Moleculin Biotech Inc (NASDAQ:MBRX) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 3,414,826 shares, a growth of 327.4% from the April 15th total of 798,955 shares. Currently, 12.4% of the company’s shares are sold short. Based on an average daily volume of 19,748,725 shares, the days-to-cover ratio is currently 0.2 days.
A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in Moleculin Biotech by 279.0% in the first quarter. Renaissance Technologies LLC now owns 157,164 shares of the company’s stock worth $127,000 after purchasing an additional 115,700 shares in the last quarter. Taylor Cottrill Erickson & Associates Inc. raised its holdings in Moleculin Biotech by 24.6% in the first quarter. Taylor Cottrill Erickson & Associates Inc. now owns 151,781 shares of the company’s stock worth $123,000 after purchasing an additional 30,000 shares in the last quarter. BB&T Corp raised its holdings in Moleculin Biotech by 55.6% in the first quarter. BB&T Corp now owns 140,000 shares of the company’s stock worth $113,000 after purchasing an additional 50,000 shares in the last quarter. Northern Trust Corp raised its holdings in Moleculin Biotech by 109.1% in the fourth quarter. Northern Trust Corp now owns 47,918 shares of the company’s stock worth $50,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Moleculin Biotech in the fourth quarter worth about $36,000. Institutional investors and hedge funds own 4.48% of the company’s stock.
NASDAQ:MBRX opened at $1.12 on Friday. Moleculin Biotech has a 1-year low of $0.78 and a 1-year high of $3.15. The stock has a market capitalization of $50.62 million, a P/E ratio of -2.20 and a beta of 2.26. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.01.
MBRX has been the subject of a number of recent analyst reports. ValuEngine lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Maxim Group reissued a “buy” rating and set a $3.00 target price on shares of Moleculin Biotech in a research note on Tuesday, February 26th. Finally, Zacks Investment Research lowered shares of Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 14th.
TRADEMARK VIOLATION WARNING: “Short Interest in Moleculin Biotech Inc (MBRX) Grows By 327.4%” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4350823/short-interest-in-moleculin-biotech-inc-mbrx-grows-by-327-4.html.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
See Also: What is the quiet period?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.